Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- R. Nolan Townsend
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Beta
- 1.65
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.16
Financials
Revenue
$0.00-100.0%Net Income
$-38.30MEBITDA
$-39.82MFree Cash Flow
$-28.86MEPS (diluted)
$-0.43Shares Outstanding (diluted)
88.68M+232.8%Operating Expenses
$40.40MCash & Debt
$194.78MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-99.96M | $-1.86 |
| 2024 | $0.00 | $-98.33M | $-3.09 |
| 2023 | $0.00 | $-66.39M | $-2.49 |
| 2022 | $654.0K | $-59.28M | $-2.36 |
| 2021 | $1.66M | $-50.62M | $-2.01 |
| 2020 | $518.5K | $-5.15M | $-0.20 |
Valuation
LXEOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·3d ago·Positive
Lexeo Therapeutics: Encouraging Gene Therapy Data, But I Want To See More Lexeo Therapeutics has two promising gene therapy candidates with LX2006 and LX2020. There are rather encouraging early clinical results and some potential to address underlying disease mechanisms. They ended 3Q26 with about $219.1 million in cash and investments, which gives them a projected runway into 2028. It's an cash-adjusted valuation with upcoming catalysts, but considerable clinical and regulatory uncertainty rema
View source ↗ - Newsmarketbeat.com·6d ago·Neutral
Lexeo Therapeutics Q3 Earnings Call Highlights Lexeo Therapeutics NASDAQ: LXEO reported interim data from a small, early-stage trial of its gene therapy LX2020, saying patients who received the higher dose showed reductions in abnormal heart rhythms and improvements in other measures of PKP2-associated arrhythmogenic cardiomyopathy.
View source ↗ - Newsglobenewswire.com·7d ago·Positive
… Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026 NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) on…
View source ↗ - Newsmarketbeat.com·28d ago·Positive
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout Lexeo Therapeutics NASDAQ: LXEO outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich's ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcare Conference.
View source ↗ - Newsmarketbeat.com·29d ago·Positive
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy Lexeo Therapeutics NASDAQ: LXEO outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
View source ↗ - Newsglobenewswire.com·45d ago·Positive
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of th…
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
…alyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson's Disease and Movement Disorders 2026 taking place October 4-8, 2026 in Seoul, Korea. “We are pleased to see LX2006 featured…
View source ↗ - Newsprnewswire.com·60d ago·Positive
…pertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.
View source ↗ - Newsglobenewswire.com·60d ago·Positive
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
View source ↗ - Newsglobenewswire.com·61d ago·Positive
…es while maintaining cash runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations support…
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.
View source ↗ - Newsglobenewswire.com·102d ago·Positive
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT de
View source ↗
Earnings
Mon, Dec 14(in 3 weeks)
Consensus estimate $-0.32 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.43 vs $-0.32miss
- Mon, May 11$-0.25 vs $-0.29beat
- Mon, Mar 30$-0.27 vs $-0.32beat
- Wed, Nov 5$-0.33 vs $-0.48beat
- Thu, Aug 14$-0.60 vs $-0.64beat
- Mon, May 12$-0.99 vs $-0.80miss
Estimates and results for LXEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LXEO officers and directors.
- Bought
- —
- Sold
- $1.1m
0 trades
44 trades
- Tamayo Louis Edwardsold
- Otero Jose Manuelsold
- Townsend Richard Nolansold
- Tamayo Louis Edwardsold
- Townsend Richard Nolansold
- Otero Jose Manuelsold
- Tamayo Louis Edwardsold
- Otero Jose Manuelsold
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LXEO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
